ArticlePakistan journal of medical sciences2026
The comparison of inflammation markers in patients with non-valvular atrial fibrillation using warfarin and switched to apixaban.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the changes in levels of inflammation markers in the patient with non-valvular atrial fibrillation (NVAF) who were on Warfarin and then switched to Apixaban. Methodology: The files of 149 consecutive patients, who had NVAF, who were previously using Warfarin, but for various reasons switched to Apixaban were screened retrospectively. Forty-one patients were excluded from the study. Last coagulation parameters were used for analysis. The evaluation of hemogram parameters in patients undergoing treatment with Warfarin, subsequently transitioning to Apixaban, revealed significant insights into various hematological indices. Notably, the Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, the Systemic Immune-Inflammation Index, Systemic Inflammation Response Index (SIRI), the aggregate index of systemic inflammation and Monocyte/Lymphocyte Ratio were meticulously assessed and compared between the groups. Results: The study involved 108 individuals with NVAF. The average lymphocyte level of the patients on Apixaban therapy was statistically significantly higher than on Warfarin therapy (p<0.001). Also, The Neutrophils (p<0.001), Monocytes (p=0.008), and Platelets (p<0.001) were significantly lower in patients treated with Apixaban compared to those on Warfarin. When the systemic inflammation indices of the patients were compared, the averages of the patients' NLR, PLR, MLR, SII, SIRI, and AISI indices were statistically and significantly lower than time on Warfarin therapy. Conclusion: Current study results suggested that Apixaban has more effective anti-inflammatory potential compared to Warfarin. The study implicates new perspectives on the anti-inflammatory effects of oral anticoagulants used in the treatment of NVAF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.